Diagnosis and Management of Vaccine-Related Thrombosis following AstraZeneca COVID-19 Vaccination: Guidance Statement from the GTH-Reference-Cited by-同舟云学术

Diagnosis and Management of Vaccine-Related Thrombosis following AstraZeneca COVID-19 Vaccination: Guidance Statement from the GTH

Published:2021-04-01 Issue: Volume: Page:
ISSN:0720-9355
Container-title:Hämostaseologie
language:de
Short-container-title:Hamostaseologie

Author:

Oldenburg Johannes¹,Klamroth Robert²,Langer Florian³,Albisetti Manuela⁴,von Auer Charis⁵,Ay Cihan⁶,Korte Wolfgang⁷,Scharf Rüdiger E.⁸,Pötzsch Bernd¹,Greinacher Andreas⁹

Affiliation:

1. Institute of Experimental Haematology and Transfusion Medicine, University Clinic Bonn, Bonn, Germany

2. Vivantes Klinikum im Friedrichshain, Klinik für Innere Medizin Angiologie und Hämostaseologie, Berlin, Germany

3. Zentrum für Onkologie, II. Medizinische Klinik und Poliklinik, Universitätsklinikum Eppendorf, Hamburg, Germany

4. Universitäts-Kinderspital Zürich, Hämatologie, Zürich, Switzerland

5. Universitätsmedizin Mainz, III. Medizinische Klinik/Hämatologie/CTH, Mainz, Germany

6. Clinical Division of Haematology and Haemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria

7. Zentrum für Labormedizin, Hämostase- und Hämophilie-Zentrum, Hämatologisches Ambulatorium, St. Gallen, Switzerland

8. Institut für Transplantationsdiagnostik und Zelltherapie/Hämostaseologie, Hämotherapie und Transfusionsmedizin, Universitätsklinikum Düsseldorf, Düsseldorf, Germany

9. Institut für Immunologie und Transfusionsmedizin, Universitätsmedizin Greifswald, Greifswald, Germany

Abstract

AbstractThe COVID-19 pandemic is an ongoing global healthcare crisis. Based on reports of atypically located thromboses following vaccination with the AstraZeneca COVID-19 vaccine, the Society of Thrombosis and Haemostasis Research (GTH) has issued guidance statements on the recognition, diagnosis, and treatment of this rare complication. It shares pathophysiological features with heparin-induced thrombocytopenia (HIT) and is referred to as vaccine-induced prothrombotic immune thrombocytopenia (VIPIT).

Publisher

Georg Thieme Verlag KG

Subject

Hematology

Link

http://www.thieme-connect.de/products/ejournals/pdf/10.1055/a-1469-7481.pdf

Reference7 articles.

1. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review;W J Wiersinga;JAMA,2020

2. Coagulopathy in COVID-19 and its implication for safe and efficacious thromboprophylaxis;F Langer;Hamostaseologie,2020

3. Risk of venous thromboembolism in patients with COVID-19: a systematic review and meta-analysis;S Nopp;Res Pract Thromb Haemost,2020

4. High-dose intravenous immunoglobulin to treat spontaneous heparin-induced thrombocytopenia syndrome;E Mohanty;J Thromb Haemost,2019

5. High-dose intravenous immunoglobulin for the treatment and prevention of heparin-induced thrombocytopenia: a review;T E Warkentin;Expert Rev Hematol,2019

Cited by 200 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adverse Cardiovascular Effects of COVID-19 Vaccination: A Systematic Review;Cardiology in Review;2024-06-06

2. Cardiac Complications and COVID-19: A Review of Life-threatening Co-morbidities;Current Cardiology Reviews;2024-05

3. How We Interpret Thrombosis with Thrombocytopenia Syndrome?;International Journal of Molecular Sciences;2024-05-01

4. Pharmacological treatments for vaccine-induced immune thrombocytopenia and thrombosis (VITT) after COVID-19 vaccination;Cochrane Database of Systematic Reviews;2024-02-29

5. The Binding of the SARS-CoV-2 Spike Protein to Platelet Factor 4: A Proposed Mechanism for the Generation of Pathogenic Antibodies;Biomolecules;2024-02-20